36.28
0.69 (1.94%)
| Penutupan Terdahulu | 35.59 |
| Buka | 35.92 |
| Jumlah Dagangan | 986,912 |
| Purata Dagangan (3B) | 1,151,150 |
| Modal Pasaran | 2,157,629,952 |
| Harga / Jualan (P/S) | 30.13 |
| Harga / Buku (P/B) | 0.840 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Jul 2026 |
| Margin Keuntungan | 1,798.26% |
| Margin Operasi (TTM) | -1,221.97% |
| EPS Cair (TTM) | 11.54 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 6.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.61% |
| Nisbah Semasa (MRQ) | 18.50 |
| Aliran Tunai Operasi (OCF TTM) | -401.46 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -237.66 M |
| Pulangan Atas Aset (ROA TTM) | -22.88% |
| Pulangan Atas Ekuiti (ROE TTM) | 60.26% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Agios Pharmaceuticals, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.50 |
|
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.65% |
| % Dimiliki oleh Institusi | 101.39% |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| CAPELLO JEFFREY D | - | - | 0 | 0 |
| OWEN ADAMS CATHERINE | - | - | 0 | 0 |
| Jumlah Keseluruhan Kuantiti Bersih | 0 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 0 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| CAPELLO JEFFREY D | Pengarah | 13 Jun 2026 | Pelaksanaan pilihan | 1,976 | - | - |
| OWEN ADAMS CATHERINE | Pengarah | 13 Jun 2026 | Pelaksanaan pilihan | 1,976 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |